Soligenix (SNGX) FCF Margin (2010 - 2024)
Soligenix's (SNGX) quarterly FCF Margin came in at 81888.43% in Q2 2024, down 8095897.0% YoY from N/an in Q3 2023, and down 7038.51% on a QoQ basis from 1147.14% in Q1 2024.
Soligenix (SNGX) FCF Margin (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of FCF Margin data on file, last reported at 81888.43% in Q2 2024.
- Quarterly FCF Margin fell 8095897.0% year-over-year to 81888.43% in Q2 2024, while the trailing twelve-month figure through Dec 2024 was 7039.92% (down 601483.0% YoY) and the FY2024 annual result came in at 7039.92%, down 601483.0% from the prior year.
- FCF Margin retreated to 81888.43% in Q2 2024, from 1147.14% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 292.27% in Q1 2020 to a low of 81888.43% in Q2 2024.
- A 5-year average of 5627.65% and a median of 1048.98% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 97271 bps — and 2024, when it plunged 8095897 bps.
- Tracing SNGX's FCF Margin over 5 years: stood at 577.22% in 2020, then sank by 92 bps to 1108.41% in 2021, then gained by 11 bps to 990.84% in 2022, then advanced by 25 bps to 746.78% in 2023, then tumbled by 10866 bps to 81888.43% in 2024.
- The last three FCF Margin figures came in at 81888.43% (Q2 2024), 1147.14% (Q1 2024), and 746.78% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 70.82% |
| 10 | Soligenix | 6.21 Mn | 6.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -81,888.43% |
| Mar 31, 2024 | -1,147.14% |
| Dec 31, 2023 | -746.78% |
| Sep 30, 2023 | -2,059.43% |
| Jun 30, 2023 | -929.46% |
| Mar 31, 2023 | -842.32% |
| Dec 31, 2022 | -990.84% |
| Sep 30, 2022 | -1,959.18% |
| Jun 30, 2022 | -1,107.12% |
| Mar 31, 2022 | -1,727.43% |
| Dec 31, 2021 | -1,108.41% |
| Sep 30, 2021 | -1,632.73% |
| Jun 30, 2021 | -772.22% |
| Mar 31, 2021 | -2,700.15% |
| Dec 31, 2020 | -577.22% |
| Sep 30, 2020 | -491.28% |
| Jun 30, 2020 | -325.25% |
| Mar 31, 2020 | -292.27% |
| Dec 31, 2019 | -133.33% |
| Sep 30, 2019 | -217.31% |